

ABSTRACT OF THE DISCLOSURE

The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF- κ B) activating pathway useful in the treatment of NF- κ B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I κ B.